Sanofi's innovative targeted nanobody drug has been approved for marketing in China.

Sanofi announced on November 5 that its innovative drug Cablivi has officially been approved by the China National Medical Products Administration for the combination treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adult and adolescent patients who are at least 12 years old and weigh at least 40 kg. As the world's first nano-antibody drug approved for market and the only targeted treatment for aTTP, Cablivi can achieve faster disease control, reduce related deaths, worsening or major thrombotic events, prevent relapse, and provide patients with a more effective and safer treatment option.